找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Asbestos and Mesothelioma; Joseph R. Testa Book 2017 Springer International Publishing AG 2017 Asbestos.Cancer Prevention.Cell Signaling.E

[復(fù)制鏈接]
樓主: Magnanimous
41#
發(fā)表于 2025-3-28 16:25:09 | 只看該作者
Malignant Pleural Mesothelioma: History, Controversy, and Future of a Man-Made Epidemic,g non-invasive biomarkers such as mesothelin, the 13-protein signature in serum, fibulin-3, circulating microRNAs and the recently discovered BAP1 cancer syndrome are highlighted. The asbestos history is a lesson not be repeated, but here we also review recent in vivo and in vitro studies showing th
42#
發(fā)表于 2025-3-28 20:55:53 | 只看該作者
43#
發(fā)表于 2025-3-28 23:48:21 | 只看該作者
44#
發(fā)表于 2025-3-29 04:52:04 | 只看該作者
45#
發(fā)表于 2025-3-29 09:05:56 | 只看該作者
46#
發(fā)表于 2025-3-29 14:37:56 | 只看該作者
3D Models of Mesothelioma in the Study of Mechanisms of Cell Survival,optotic family expression, and autophagy. In general, cells in a 3D setting show many differences compared to the same cells in a 2D monolayer. Many of these differences appear to contribute to cell survival. In many cases, these features can be shown to be more similar to those in the actual tumor.
47#
發(fā)表于 2025-3-29 17:59:35 | 只看該作者
Biomarkers of Response to Asbestos Exposure,onchoalveolar lavage fluid. This makes direct exposure assessments very difficult. In contrast, biomarkers of response, which reflect a change in biologic function in response to asbestos exposure, have proved to be more useful. MM is the major biological response to asbestos that can be readily mon
48#
發(fā)表于 2025-3-29 23:33:51 | 只看該作者
Immunotherapeutic Approaches to Mesothelioma,Of these, the monoclonal antibody amatuximab and an antibody-drug conjugate anetumab ravtansine are undergoing registration trials. Ongoing research is focused on better understanding the antitumor responses to immune-based approaches and to prospectively identify patients who are more likely to res
49#
發(fā)表于 2025-3-30 01:40:00 | 只看該作者
50#
發(fā)表于 2025-3-30 04:37:03 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-11-3 04:14
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
新和县| 咸阳市| 萝北县| 阜宁县| 凤城市| 交城县| 阿鲁科尔沁旗| 呼图壁县| 库尔勒市| 黔西县| 璧山县| 太白县| 平邑县| 中阳县| 米易县| 会东县| 江油市| 玉龙| 当雄县| 准格尔旗| 永川市| 洪雅县| 六盘水市| 武邑县| 侯马市| 林口县| 渝北区| 洛隆县| 霍城县| 肃北| 青川县| 漳浦县| 凤山市| 界首市| 密云县| 抚宁县| 雅安市| 沭阳县| 西峡县| 封丘县| 曲麻莱县|